Discover 172 paid clinical trials in Maine. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Maine offers nearby opportunities for both healthy volunteers seeking paid studies and individuals with specific health conditions to participate in valuable research. Major research centers in Portland, Bangor, and Augusta are actively recruiting, providing easy access to advanced medical care and new treatment options.
Filter
1
Filter results
Results: 172
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
for
Hodgkin Lymphoma in Remission, Leukemia in Remission,
Location: Scarborough ME, Boston MA, Providence RI, New Haven CT,
Sponsor: Children's Oncology Group
Sex: All
Age: 0+
Code: NCT01790152
Recruiting
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
for
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma,
Location: St. John's, Halifax, Bangor ME, Scarborough ME,
Sponsor: Children's Oncology Group
Sex: All
Age: 1 - 25
Code: NCT03959085
Phase3, Recruiting
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
for
Embryonal Rhabdomyosarcoma,
Location: Halifax, Scarborough ME, Boston MA, Providence RI,
Sponsor: Children's Oncology Group
Sex: All
Age: 0 - 21
Code: NCT05304585
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
for
Ovarian Carcinoma
Location: Portland ME, Scarborough ME, Boston MA, Providence RI,
Sponsor: NRG Oncology
Sex: Female
Age: 35 - 50
Code: NCT04251052
Recruiting
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
for
Atrial Fibrillation (AF)
Location: Mira Road, Halifax, Bangor ME, Fall River MA, Boston MA,
Sponsor: Anthos Therapeutics, Inc.
Sex: All
Age: 65+
Code: NCT05712200
Phase3, Recruiting
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Location: St. John's, Halifax, Bangor ME, Scarborough ME,
Sponsor: Children's Oncology Group
Sex: All
Age: 0 - 30
Code: NCT04322318
Phase2, Recruiting
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Saint John, Damariscotta ME, Brunswick ME, Augusta ME,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT04269902
Phase3, Recruiting
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
for
Muscle Invasive Bladder Urothelial Carcinoma,
Location: Brewer ME, Gloucester MA, South Weymouth MA, Beverly MA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT05987241
Phase2, Phase3, Recruiting
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study